Please assess the completion status of the following clinical trial:

Trial Title: Ixabepilone With or Without Estramustine in Treating Patients With Progressive Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed adenocarcinoma of the prostate~* Must have disease progression meeting 1 of the following criteria:~  * Rising prostate-specific antigen (PSA) on at least 3 consecutive measurements taken more than 1 week apart~ * Measurable disease, defined as new or progressive soft tissue masses on CT scan or MRI~ * New metastatic lesions by radionuclide bone scan~* The most recent PSA must be at least 4 ng/mL if no measurable disease is present~* Ineligible if sole manifestation of progressive disease is an increase in disease-related symptoms~* Serum testosterone no greater than 50 ng/mL~* One of the following therapies for maintenance of castrate status required:~  * Must continue on gonadotropin-releasing hormone analogs (e.g., leuprolide or goserelin) to maintain castrate levels of serum testosterone~    * Developed disease progression after discontinuation of the antiandrogen that was part of the first-line hormonal therapy~ * Prior surgical orchiectomy~* Developed disease progression after discontinuation of megestrol~* No known brain metastases~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* Karnofsky 70-100%~Life expectancy:~* Not specified~Hematopoietic:~* WBC at least 3,000/mm\^3~* Absolute neutrophil count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~* No history of bleeding disorder that would preclude anticoagulation with warfarin~Hepatic:~* Bilirubin normal~* AST/ALT no greater than 2.5 times upper limit of normal (ULN)~* PT/PTT normal (unless anticoagulated for other reasons \[e.g., atrial fibrillation\])~Renal:~* Creatinine no greater than 1.5 times ULN~Cardiovascular:~* No significant cardiovascular disease~* No symptomatic congestive heart failure~* No New York Heart Association class III or IV heart disease~* No active unstable angina pectoris~* No cardiac arrhythmia~* No myocardial infarction within the past 6 months~* No history of hemorrhagic or thrombotic cerebrovascular accident or deep venous thrombosis within the past 6 months~Pulmonary:~* No pulmonary embolism within the past 6 months~Other:~* Fertile patients must use effective contraception~* No history of allergic reactions to compounds of similar chemical or biological composition to the epothilones~* No history of recent gastrointestinal bleeding that would preclude anticoagulation with warfarin~* No other concurrent active malignancy except nonmelanomatous skin cancer~  * Disease not considered currently active if completely treated with less than a 30% risk for relapse~* No other concurrent uncontrolled illness~* No ongoing or active infection~* No psychiatric illness or social situation that would preclude study compliance~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* No concurrent routine filgrastim (G-CSF) or sargramostim (GM-CSF) except for neutropenic fever~* No concurrent immunotherapy~Chemotherapy:~* No prior chemotherapy~* No other concurrent chemotherapy~Endocrine therapy:~* See Disease Characteristics~Radiotherapy:~* No prior palliative radiotherapy to more than 25% of bone marrow~* No prior radioisotope therapy with strontium chloride Sr 89 or samarium Sm 153 lexidronam pentasodium~* No concurrent therapeutic radiotherapy~* Concurrent focal radiotherapy for palliation of bone disease-related symptoms allowed at the investigator's discretion~Surgery:~* See Disease Characteristics~* At least 4 weeks since prior major surgery~Other:~* No other concurrent anticancer investigational or commercial agents or therapies~* No concurrent herbal, alternative, or food supplements (e.g., PC-SPES, saw palmetto, or St. John's Wort)~* No concurrent combination antiretroviral therapy for HIV-positive patients~* No initiation of bisphosphonates immediately before or during study~* Concurrent bisphosphonates allowed if developed disease progression while on stable doses~* Concurrent daily multivitamin allowed

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete